#USA #Bethlehem #Cell Therapy #ABEC #ATB-2100

ABEC Revolutionizes Advanced Therapy Manufacturing with ATB™-2100

ABEC, a prominent name in biopharmaceutical engineering solutions, has officially launched its latest innovation, the ATB™-2100. This state-of-the-art bioreactor for advanced therapy manufacturing aims to address the pressing demands for scalable, efficient, and automated manufacturing processes crucial in gene and cell therapies. As the industry grapples with challenges in scaling production while maintaining quality and affordability, the ATB™-2100 emerges as a game changer intended to streamline the journey from preclinical development to commercial-scale manufacturing.

A Unique Approach to Cell Expansion

The ATB™-2100 introduces an unprecedented design for cell processing, focusing on fully closed and automated systems. This innovative approach allows continuous nutrient and gas flow within cell cultures while effectively eliminating metabolic waste. The bioreactor’s design ensures high viability and density of cells by mimicking the natural human circulatory system, creating a low shear stress environment conducive to cellular growth. Thus, ABEC's proprietary hollow fiber perfusion membrane network plays a crucial role, enhancing cellular expansion capabilities for various cell types, including T cells, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs).

Scalability Without Compromise

One of the standout features of the ATB™-2100 is its remarkable scalability. Unlike conventional cell expansion technologies that require drastic redesigns during scaling, this platform maintains a consistent ratio between membrane surface area and volume across a range of bioreactor capacities, from 200 ml to 10 liters. This streamlined scalability significantly reduces development timelines, minimizes technological transfer risks, and accelerates market entry. As Scott Pickering, CEO of ABEC, aptly noted, "Cell and gene therapies face significant development challenges that hinder scalability, inflate costs, and delay commercialization. The ATB™-2100 overcomes these hurdles and represents a transformative step forward in our field."

Implications for the Biopharmaceutical Industry

The implications of the ATB™-2100 for the biopharmaceutical industry are profound. It promises to address longstanding issues in therapy development, making it possible to meet the increasing demand for advanced therapies. The focus on automation and process reproducibility also ensures that therapies can be produced efficiently and consistently, thereby enhancing overall productivity and lowering costs across the board.

To learn more about the ATB™-2100 bioreactor platform, visit www.abec.com or reach out via [email protected]. With over 50 years of experience, ABEC stands at the forefront of engineering solutions and services for biopharmaceutical manufacturing, continually pursuing innovations that enhance global productivity and market responsiveness.

In summary, the launch of the ATB™-2100 by ABEC is a crucial development in the field of advanced therapies, promising to revolutionize how these life-changing treatments are developed and manufactured. The future of biopharmaceuticals looks brighter with such technological advancements leading the way.